Along this line, passive therapy with human–mouse chimeric, high-affinity anti-SEB antibodies mitigated the systemic inflammatory response that occurs during pneumonia caused by SEB-producing S. aureus. This evidence concerns the gene SETBP1 and susceptibility to pneumonia measurement.